.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,066,942

« Back to Dashboard

Claims for Patent: 9,066,942

Title:Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
Abstract: The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4.times.10.sup.-4 moles to about 2.0.times.10.sup.-3 moles.
Inventor(s): Giliyar; Chandrashekar (Salt Lake City, UT), Nachaegari; Satish Kumar (Salt Lake City, UT), Nachiappan; Chidambaram (Sandy, UT), Patel; Mahesh V. (Salt Lake City, UT), Venkateshwaran; Srinivansan (Salt Lake City, UT)
Assignee: Spriaso LLC (Salt Lake City, UT)
Application Number:14/194,523
Patent Claims: 1. A method of treatment, said method comprising: administering to an individual having cough or cold, twice a day, a pharmaceutical composition which is a solid monolithic matrix tablet comprising 54 mg of codeine phosphate, 8 mg chlorpheniramine maleate or a pharmaceutically acceptable salt of chlorpheniramine and from 60 mg to 125 mg of a release rate controlling non-ionic oxyl-containing hydrophilic polymer.

2. The method of claim 1 wherein said release rate controlling non-ionic oxyl-containing hydrophilic polymer is hydroxypropyl methylcellulose.

3. The method of claim 2 wherein the ratio of total molar content of oxyl groups in the release rate controlling non-ionic oxyl-containing hydrophilic polymer to the total molar content of the oxygen groups in the codeine is about 2.5 to about 9.0.

4. The method of claim 1 wherein single dose administration of the pharmaceutical composition provides therapeutic levels of codeine, chlorpheniramine, or both, for about 12 hours.

5. The method of claim 1 wherein single dose administration of the pharmaceutical composition provides cough or cold symptom relief for about 12 hours.

6. The method of claim 1 wherein said pharmaceutical composition further comprises pseudoephedrine.

7. The method of claim 1 wherein said release rate controlling non-ionic oxyl-containing hydrophilic polymer is hydroxypropyl cellulose, methyl cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, or a combination thereof.

8. The method of claim 1 wherein the release rate controlling non-ionic oxyl-containing hydrophilic polymer is hydroxypropyl methyl cellulose (HPMC) which has an average methoxy content of about 15 mole % to about 30 mole %.

9. The method of claim 1 wherein said pharmaceutical composition is resistant to alcohol extraction.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc